Abstract Background Medication review with follow-up (MRF) is a professional pharmacy service proven to be costeffective. Its broader implementation is limited, mainly due to the lack of evidence-based implementation programs that include economic and financial analysis. Objective To analyse the costs and estimate the price of providing and implementing MRF. Setting Community pharmacy in Spain. Method Elderly patients using poly-pharmacy received a community pharmacist-led MRF for 6 months. The cost analysis was based on the time-driven activity based costing model and included the provider costs, initial investment costs and maintenance expenses. The service price was estimated using the labour costs, costs associated with service provision, potential number of patients receiving the service and markup. Main outcome measures Costs and potential price of MRF. Results A mean time of 404.4 (SD 232.2) was spent on service provision and was extrapolated to annual costs. Service provider cost per patient ranged from €196 (SD 90.5) to €310 (SD 164.4). The mean initial investment per pharmacy was €4594 and the mean annual maintenance costs €3,068. Largest items contributing to cost were initial staff training, continuing education and renting of the patient counselling area. The potential service price ranged from €237 to €628 per patient a year. Conclusion Time spent by the service provider accounted for 75-95% of the final cost, followed by initial investment costs and maintenance costs. Remuneration for professional pharmacy services provision must cover service costs and appropriate profit, allowing for their long-term sustainability.
Introduction
Health care systems are facing significant challenges worldwide. These systems are under growing economic pressure, driven by the changing needs and expectations of the population, the increasing burden of chronic diseases, and maintaining universal access to health care [1] . Effective management of health care is critical, and often Electronic supplementary material The online version of this article (doi:10.1007/s11096-017-0454-2) contains supplementary material, which is available to authorized users. involves policies limiting costs. All health care providers are under increasing scrutiny, as policymakers try to implement new strategies that guarantee the sustainability of health care systems. Various models of health care have been proposed as possible solutions [1] .
The use of medicines is the most common modality and cost-effective way of treating chronic conditions, representing one of the highest costs in healthcare systems. However, inappropriate use of medications is prevalent and is associated with negative clinical outcomes and economic consequences [2, 3] , with elderly polypharmacy patients at higher risk [4] . Therefore new policies, strategies and services are required to ensure medications are used in an effective and safe manner.
Pharmacist-led medication review services are considered to be a potential policy solution to this problem. Pharmacists are changing their professional practice towards a more patient centred approach. They have been shown to optimal deliver health outcomes and a more sustainable health care, through the provision of professional pharmacy services (PPS). These are services oriented towards optimising medication use and health care to individuals. PPS have been shown to have a positive impact in terms of clinical, economic and humanistic outcomes [5] [6] [7] [8] [9] . Specifically medication review with followup (MRF) is a type of PPS proven to be a cost-effective intervention [10] . However, its broader implementation to practice is limited, mainly due to the lack of evidencebased implementation programs that include the economic and financial analysis [11] .
From a professional perspective, pharmacists are willing to provide these patient-centred services. However, the provision of services like MRF represents a business activity and similarly to any other business, generates costs [12] . The assessment of the costs of any activity allows payers and business managers to determine if it will be economically advantageous for the health care system, for the business organization and be sustainable over time [13] . Thus, health care decision makers need to know the costs associated with service provision and implementation to determine its viability over time. Concurrently, pharmacies need to determine their costs to assess the economic viability and long-term sustainability, prior to making the strategic decision to implement [14] [15] [16] [17] . Despite its importance, there is a paucity of cost analysis research for most types of PPS. For example, less than half of the studies included in two systematic reviews on economic evaluations of PPS included full identification and evaluation of costs incurred, nor did they had a price setting process [18, 19] . Without this data, a broader implementation of cost-effective and evidence-based services like MRF will be challenging.
Aim of the study
The conSIGUE program was a research study that promoted the provision of MRF to elderly patients using polypharmacy, with the ultimate goal of achieving its implementation and integration into the usual professional practice of community pharmacists [20] . The first phase of the program aimed at evaluating its clinical, economic and humanistic impact [21] . As part of the economic evaluation [10] , a cost analysis was undertaken. The primary objective of the present sub-study was to estimate the costs and potential price of providing and implementing MRF to aged patients using polypharmacy. Secondary objectives included identifying the main cost drivers of service provision and determining the impact of changes to service provision on the cost estimate.
Ethics approval
Ethical approval was obtained from the Ethics and Research Committee of the Virgen de las Nieves University Hospital (Granada, Spain). Informed consent was obtained from all individual participants included in the study.
Method Study design
Elderly patients (over 64 years old) using poly-pharmacy (use of five medications or more) participated in the study. Patients received a community pharmacist-led MRF for 6 months. Community pharmacists in the Spanish provinces of Granada, Gipuzkoa, Las Palmas and Santa Cruz de Tenerife provided the service. The study methodology has been fully described elsewhere [10] .
Pharmacist intervention-medication review with follow-up MRF was provided in a private counseling area and according to national guidelines [22] . MRF consists of seven stages: (A) a face to face first interview with the patient, in order to gather relevant information about the health problems and medications used, (B) an initial assessment of the patient's clinical situation, (C) a study phase, (D) a advanced medication review focussed on identifying drug related problems and negative outcomes associated with medications, (E) an action plan, (F) the delivery of interventions aimed at addressing drug related problems and negative outcomes associated with medications, targeted at both patients and other health care professionals and (G) follow-up visits (based on the needs of each patient).
Cost analysis method
The cost analysis was based on the time-driven activity based costing method (TDABC) [13] . It was considered to be a suitable option, as it attempts to quantify all the costs involved in delivering a service and to estimate its price [23, 24] . The TDABC requires estimates of the unit cost of supplying capacity and of the time required to perform the different activities necessary to provide a service.
Data collection
Relevant data for the cost analysis was obtained using prepiloted questionnaire (Electronic supplementary material) that was administered to all service providers at the end of the study. The questionnaire had been generated and tested in a qualitative study with pharmacists who had previous experience with MRF provision [25] . Additionally, the time invested by the service providers on each of the MRF stages was collected for every patient through all the study periods. This data was prospectively collected by the service providers at the time of service provision using a time recorder and documented in the study data collection forms. Time data was included in the sub-study if it had been recorded for at least six out of the seven stages of the MRF service. Missing values were supplemented using the median time of the corresponding MRF stage.
Variables included in the cost analysis

Service provider cost
Service provider cost was defined as the cost of the time spent by the pharmacist on providing the MRF service for 1 year. To calculate this value, the time (in minutes) spent on MRF provision was multiplied by the cost of labour for 1 min worth of the pharmacist's effective work (Fig. 1 ). To extrapolate from the 6-month to the 12-month data, we adopted a conservative approach and doubled the time taken for the monthly follow up visits. To calculate this effective work minute value, four elements were assessed:
• Pharmacist's working time per year-determined by national agreements. • Pharmacist's gross salary-determined by the employee's wages and described in the national agreements between community pharmacists and pharmacy owners [26] . As there is no official document that determines the nominal salary for pharmacy owners this was estimated to be equal to the annual net profit from the business. This information was obtained from a report published annually on the financial-fiscal trends of Spanish community pharmacies [27] .
• Taxes-mandatory employer's payments to the National Health Insurance [28, 29] . • Pharmacist's non-working paid time-proportion of time that is not considered to be effective working time.
For the purpose of this study, 5881 min of non-working paid time a year was estimated [30] .
Initial investment and maintenance costs
The costs of the resources required to provide the service were classified into two categories: (A) initial investment costs [25] and (B) maintenance costs [31] . Table 1 details the initial investment and maintenance cost items. They were calculated as follows:
• For each resource, budget estimates were sourced from the following suppliers: (a) a regular supplier of the pharmacy, (b) suppliers with broad distribution in Spain and (c) commercial establishments through their Internet Webpage. The mean of the three estimates was calculated for each resource and was used as an average acquisition value.
• To estimate the cost of the patient counselling area, a building engineer quoted for participant pharmacies that lacked this space. The mean value per square meter was calculated.
• As the resources and the counselling area can be used to provide different services besides MRF, the allocation to MRF provision was estimated.
Price of the MRF service
The potential price for the MRF service was estimated using different case scenarios and taking into account the following variables ( Fig. 2 ):
• Service provider costs-this value was considered to be the same for each patient receiving the service, but • Potential number of patients receiving the service-this information indicated the 'productivity' of the pharmacy, and reflected the potential number of patients that could receive the service with the available resources [32] .
• Investment amortization-this was the allocation of the investment costs over a period of time [33] . According to European regulations, the initial investment, the staff training, the equipment material, the annual subscriptions and the counselling area are all amortizable [34] . The amortization was considered over 5 years.
• Maintenance expenses-they were estimated as the projected annual expenses needed to deliver the service divided by the number of patients receiving it in a year.
• Mark-up applied-the mark-up on the cost of the service used were 10, 20, 30 and 40%, in order to reflect current mark-ups used by European national health systems [35, 36] .
Break-even analysis
Additionally, a break-even analysis was calculated in order to estimate the minimum number of patients required for the MRF service to be provided without loss to the pharmacy. The break-even point was calculated based on the Bibliographic resources Fixed The acquisition cost of bibliographic resources was divided by the number of services requiring its use.
Initial staff training costs Fixed The initial training costs needed to provide the service was multiplied by the number of service providers.
Maintenance costs
Renting of the counselling area Fixed The rental cost of the counselling area was pro-rated relatively to the whole pharmacy premises and it was then divided by the number of services delivered in that space.
Utilities (electricity, water, etc.) Variable The cost of the utilities was pro-rated by the counselling area, and it was then divided by the number of services delivered in that space.
Equipment materials (reagents, gloves, etc.)
Variable The cost of the equipment material was pro-rated according to the number of services whose provisions require the use of the equipment.
Subscriptions (magazines, software, etc.)
Fixed
The cost of the subscriptions was pro-rated according to the number of services whose provisions require the use of the subscriptions.
Continuous education Fixed
The annual continuous education cost was divided by the number of service providers attending it.
Both
General staff expenses (Administrative, not labour) fixed costs (costs that do not vary with the number of patients receiving the service), variable costs (costs that vary with the number of patients receiving the service) and service price (Fig. 3) . We assumed an allocation of 70% of a full time pharmacists time to service provision. The break-even analysis was undertaken using various scenarios, as described below:
• Scenario 1: Service provided by a pharmacist in charge, with a 10% mark up and a service price of 243 per patient a year. 
Statistical analysis
SPSS version 15.0 (SPSS Inc., Chicago, IL, USA) was used for analysing the data. Mean and standard deviations (SD) were used to summarize continuous variables. Categorical variables were described using frequencies and percentages. To compare quantitative variables, Student's t test and analysis of variance for independent samples were used. Chi squared test was performed for comparison of proportions.
Results
Sixty-two of the 99 (62.6%) pharmacists providing the service during the study completed the questionnaire. Four questionnaires were discarded due to missing information. Most of the pharmacies were located in cities and towns with more than 10,000 inhabitants. The pharmacists included in this analysis provided the MRF service to 523 patients. A mean of 404.4 (SD 232.2) minutes per service provider was spent on service provision during 6 months of follow-up. 40% of this time (157.9 min) was spent on patient follow-up visits. Time spent on service provision increased up to 560.3 (SD 279.9) minutes when extrapolated to annual values (Tables 2, 3 ). 56% of this time (315.8 min) was spent on patient follow-up. On average, the cost of the service provider ranged from 248.3€ (SD 116.5) in the case of a pharmacist in charge, to 310.1€ (SD 164.4) in the case of a pharmacy owner (Table 4) . Investment costs accounted for 4594.19€ per pharmacy, with initial staff training representing the highest cost in this category, followed by equipment (Table 5 ). Annual maintenance costs were estimated to be 3068.58€. Continuing education was considered to be the highest maintenance cost, followed by the renting of the counselling area (Table 5) . Table 6 shows the estimated prices for the MRF service per patient and a year. Results are shown using different case scenarios, taking into account the professional level of the service provider, the potential number of patients receiving the service and the mark up applied. The lowest estimated price was €237 a year, when the service was delivered by a pharmacist in charge to a maximum of 120 patients a year and applying a mark up of 20%. The highest estimated service price was €628 per patient a year. It corresponded to a MRF service provided by a pharmacy owner, in a pharmacy where a maximum of 60 patients per year would receive the service and applying a mark-up of 40%.
Depending on the scenario, the break-even point varied from a minimum of 91 patients (Scenario 6), to a maximum of 129 (Scenario 1). The four other scenarios (Scenarios 2, 3, 4 and 5) gave 114, 115, 111 and 100 patients respectively.
Discussion
This cost analysis provides evidence on the costs of delivering community pharmacy-led MRF services to elderly patients using polypharmacy. We identified that the highest cost in delivering such service was the cost of the service provider, accounting for 75-95% of the final cost. There were though, significant differential costs depending on the provideŕs professional level. For example, according to the different case scenarios proposed, the highest cost was achieved when the service provider was a pharmacy owner. Similarly less experienced pharmacists with lowest labour contractual would be less costly. However, whether this professional level can affect the cost-effectiveness of the service, which has already been assessed using experienced pharmacists [10] , remains unknown. This opens the debate of accessibility and quality of service provision. The quality of the service may be dependant on the underlying capacity, experience and educational qualifications of the service provider. The question is therefore, if there is a need for accredited pharmacists to provide the service with the associated labour costs equally applying across all types of pharmacies, or if registered pharmacists can provide the service at the right quality with lower labour costs. Specialized staff training was the cost that had the greatest impact on the initial investment. Importantly and from an economic perspective, it would be essential to agree on the minimum level of competency required to provide this kind of services and on the accreditation process. Interestingly, only 23% of the professional pharmacy service programs currently implemented at an international level, require additional training or further accreditation for the service provider [37] . Building and furnishing a patient counselling area was the second highest initial cost identified [38] . Unless remuneration for service provision is established, it would be impossible for the pharmacy to perceive the return of this investment on the space allocated. Similarly to previous studies, our service providers stated the need to acquire new laboratory material, in order to monitor health parameters of patients. Without this technology pharmacists would not be able to provide specific clinical parameters to other health care professionals like general medical practitioners [25] . The use of this kind of technology has been previously described as an enabler but not the sole facilitator for the implementation of MRF services [39] . A similar trend was observed for maintenance costs, with continuing education resulting in the highest maintenance cost followed by the rental cost of the counselling area. This fact reinforces the debate of accreditation and remuneration for service provision to ensure its sustainability over time.
Interestingly, the prices estimated in this study would make the service sustainable over time. There might be a concern that health care purchasers may be find that the length of time spent on these patients, 9.3 h in the first year of the service, would act as barrier to financing the service. However, the MRF service has been shown to be a cost effective technology for the health care system [10] . Based on the different scenarios proposed, the break-even point seems quite achievable. If one presumes that pharmacies are using labour effectively, the most likely model would be that pharmacies would employ a full time service provider to deliver the service. In the break-even analysis, we allocated 70% of the time of a full time pharmacist to service provision. However, it has been reported that the time invested in service provision seems to decrease as the number of patients and time of follow-up increase [40] . This means more patients could benefit from the service as the provider becomes more experienced and the service integrates into routine practice of the pharmacy. This study, in identifying and assessing the type of costs associated with the provision of a professional pharmacy service, recognised that reimbursement models need to take into account the major elements that drive service price [41] , both from the perspective of the payer and the pharmacy. Service remuneration from the payer's perspective is dependant on the clinical and economic outcomes achieved for the health care system. Various types of remuneration systems currently exist for PPS including a fee for service, capitation fee, or outcome based payment [42] . The fee for service model of payment appears to be the most appropriate as a compensation model that boosts the development and implementation of new PPS [35] . This model is already being used for services such as medication therapy management (MTM) in USA (except in the state of Minnesota), Standard Medication Management Assessment and Comprehensive Annual Care Plan in Canada, Medication Use Review and Adherence Support in New Zealand and Home Medication Review in Australia [37] . From a business perspective, this fee for service model encourages service provision on a volume-based approach. However, in the capitation system model, the payment is made based on a number of patients served by the pharmacy over a fixed period of time. This model is preferred by some managers, as it fixes the costs [43] . It has the disadvantage, however, that the payment is made whether or not services are actually provided. Therefore, it does not encourage the implementation of any new PPS. The remuneration model which probably best fits with the provision of MRF, is an outcome-based payment. This model is being applied in Fairview Pharmacy Services' MTM program and the final price is fixed according to the complexity of the case [44] . Impact data is crucial to demonstrate a return on investment in these services from a payer perspective and to demonstrate the impact of pharmacist interventions on patient care and health outcomes [45] . Nevertheless, taking into account the historical context of European and Anglo Saxon health systems driven by mark-up systems, a fee for service seems to be the most feasible reimbursement method. Professional pharmacy services remuneration has been identified as an enabler for change for professional pharmacy practice to optimize patient care and assist in the sustainability of the overall health care systems care [38, 46] . In many countries PPS are predicted by pharmacy organisations, academics and other experts to be the future of the profession practice. However, it is fundamental that the amount of compensation covers service costs and generates enough profit, so these cost-effective services can be sustainable over time. Some limitations must be mentioned. A national mean for the service cost has been reported. However, the developed political powers at a regional level in Spain significantly differ in labour and business costs and health funding, providing a wide range for the potential pricing of MRF. The largest item contributing to the cost of the MRF service was the service provider's time. In this study, the time was recorded by the providers and therefore was not independently measured and had high variability. However, this variable was prospectively collected for all study periods and patients, and unlike similar studies in this field, was not based on estimates. Additional variability occurred as many labour costs, educational qualifications, and level of experience of the service providers varied from province to province. The participating pharmacists did not have much previous experience in service provision, which may have increased the times at the early stages of the study. A separate counselling area did not exist in some pharmacies and therefore it was included in the investment costs. The cost of purchasing equipment was divided as a function of the number of services delivered, since different services can be provided using the same equipment as the one needed to provide MRF. Finally, the price of the service was calculated considering an average time for service provision per patient. This has been done regardless of the complexity of each patients case, resulting in large variability.
Conclusion
This cost analysis provides evidence on the costs of providing and implementing community pharmacy-led MRF services to elderly patients using polypharmacy. Time spent by the service provider accounted for 75-95% of the final cost, followed by initial investment costs and maintenance costs. If governments and other payers, as part of their strategy to optimise quality use of medicines, wish to promote community pharmacies as providers of professional pharmacy services, it is paramount that the amount of compensation covers service costs and generates enough profit. More attention should be given to the viability of the underlying structure and business supporting this service delivery.
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